Biodesix Reports FY25 Revenue of $88.5 Million
Total revenue is estimated to be $28.8M and $88.5M for the fourth quarter and fiscal 2025, respectively, an increase of 41% and 24% over the respective prior year comparable periods. FY25 revenue consensus $84.74M. "Biodesix finished 2025 with a strong fourth quarter delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million," said Scott Hutton, CEO. "Throughout the year, we delivered accelerating growth in our Lung Diagnostics testing revenue, driven by an increase in test volumes and continued expansion of reimbursement. We also grew our Development Services revenue while advancing key partnerships. 2025 was another significant year for Biodesix as we presented and published new clinical and health economic data that directly support both our on-market and pipeline products. Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter. I am exceptionally proud of the Biodesix team's accomplishments in 2025 and their unwavering commitment to the healthcare professionals and the patients we serve. I look forward to building on this momentum in 2026."
Trade with 70% Backtested Accuracy
Analyst Views on BDSX
About BDSX
About the author
Friedland Enterprises Acquires 5% Stake in Lulu's Fashion Lounge
- Share Acquisition: Friedland Enterprises announced the acquisition of approximately 5% of the outstanding shares of Lulu's Fashion Lounge, aiming to enhance its market influence in the fashion retail sector and potentially provide greater strategic flexibility.
- Market Signal: This acquisition indicates Friedland's confidence in Lulu's future growth potential, which may attract other investors' attention, thereby increasing Lulu's market valuation and investment appeal.
- Investment Strategy: By increasing its stake, Friedland plans to exert greater influence over Lulu's decision-making, driving business development and brand strategy, further solidifying its position in the competitive fashion industry.
- Industry Consolidation: This transaction may signal a trend of consolidation in the fashion retail sector, with Friedland's move potentially inspiring other investors to pursue similar acquisitions to seek higher market share and synergies.
Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
NASDAQ 100 Pre-Market Indicator Drops 170.91 Points
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator has dropped by 170.91 points to 25,595.35, indicating a weak market sentiment that may impact investor confidence.
- Active Stocks: Biodesix, Inc. (BDSX) rose by 1.2 to $6.66 with a trading volume of 10,058,408 shares, reflecting a positive market response to its buy recommendation.
- Price Fluctuations: Direxion Daily TSLA Bull 2X Shares (TSLL) fell by 0.3102 to $18.26 with a volume of 4,966,541 shares, representing a 190.3% increase from its 52-week low, highlighting strong market interest in Tesla.
- Target Price Proximity: Novo Nordisk A/S (NVO) increased by 1.1 to $59.91 with 817,870 shares traded, currently at 112.3% of its target price of $53.35, indicating optimistic market expectations for its future performance.
Biodesix (BDSX) Reports 22% Revenue Growth for 2025, Stock Surges 31.87%
- Significant Revenue Growth: Biodesix's estimated full-year revenue for 2025 is $88.5 million, a 24% increase from $71.3 million last year, exceeding the updated guidance range of $84-$86 million announced on November 3, indicating strong market performance.
- Impressive Q4 Results: The estimated revenue for the fourth quarter is $28.8 million, up 41% from $20.4 million in the same quarter last year, with Lung Diagnostics revenue reaching $25.2 million, a 47% increase, reflecting growth in test volumes and higher average revenue per test.
- Positive Adjusted EBITDA: The company affirmed a positive Adjusted EBITDA compared to a loss of $3.9 million in the same quarter last year, indicating significant progress in cost control and operational efficiency, enhancing confidence in future profitability.
- Positive Stock Reaction: Following the earnings report, BDSX's stock surged 31.87% in pre-market trading to $7.21, reflecting investor optimism regarding the company's growth potential.
Biodesix Reports $88.5M Revenue for 2025, Up 24%
- Significant Revenue Growth: Biodesix anticipates total revenue of $88.5 million for 2025, representing a 24% increase, exceeding the upper limit of the company's revised guidance, indicating strong performance in the lung diagnostics sector.
- Lung Diagnostics Revenue Surge: The estimated lung diagnostics revenue for 2025 is $79.2 million, up 22% year-over-year, with Q4 revenue at $25.2 million, reflecting a 47% increase driven by higher test volumes and expanded reimbursement.
- Strong Cash Position: As of December 31, 2025, Biodesix reported cash and cash equivalents of $19.0 million, a 14% increase from Q3 2025, providing a solid financial foundation for future operations and investments.
- Positive Adjusted EBITDA Outlook: The company affirms expectations of positive Adjusted EBITDA for Q4 2025, indicating improving profitability supported by sustained revenue growth and operational leverage.
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
Friedland Enterprises Acquires 5% Stake in Lulu's Fashion Lounge
- Share Acquisition: Friedland Enterprises announced the acquisition of approximately 5% of the outstanding shares of Lulu's Fashion Lounge, aiming to enhance its market influence in the fashion retail sector and potentially provide greater strategic flexibility.
- Market Signal: This acquisition indicates Friedland's confidence in Lulu's future growth potential, which may attract other investors' attention, thereby increasing Lulu's market valuation and investment appeal.
- Investment Strategy: By increasing its stake, Friedland plans to exert greater influence over Lulu's decision-making, driving business development and brand strategy, further solidifying its position in the competitive fashion industry.
- Industry Consolidation: This transaction may signal a trend of consolidation in the fashion retail sector, with Friedland's move potentially inspiring other investors to pursue similar acquisitions to seek higher market share and synergies.
Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
NASDAQ 100 Pre-Market Indicator Drops 170.91 Points
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator has dropped by 170.91 points to 25,595.35, indicating a weak market sentiment that may impact investor confidence.
- Active Stocks: Biodesix, Inc. (BDSX) rose by 1.2 to $6.66 with a trading volume of 10,058,408 shares, reflecting a positive market response to its buy recommendation.
- Price Fluctuations: Direxion Daily TSLA Bull 2X Shares (TSLL) fell by 0.3102 to $18.26 with a volume of 4,966,541 shares, representing a 190.3% increase from its 52-week low, highlighting strong market interest in Tesla.
- Target Price Proximity: Novo Nordisk A/S (NVO) increased by 1.1 to $59.91 with 817,870 shares traded, currently at 112.3% of its target price of $53.35, indicating optimistic market expectations for its future performance.
Biodesix (BDSX) Reports 22% Revenue Growth for 2025, Stock Surges 31.87%
- Significant Revenue Growth: Biodesix's estimated full-year revenue for 2025 is $88.5 million, a 24% increase from $71.3 million last year, exceeding the updated guidance range of $84-$86 million announced on November 3, indicating strong market performance.
- Impressive Q4 Results: The estimated revenue for the fourth quarter is $28.8 million, up 41% from $20.4 million in the same quarter last year, with Lung Diagnostics revenue reaching $25.2 million, a 47% increase, reflecting growth in test volumes and higher average revenue per test.
- Positive Adjusted EBITDA: The company affirmed a positive Adjusted EBITDA compared to a loss of $3.9 million in the same quarter last year, indicating significant progress in cost control and operational efficiency, enhancing confidence in future profitability.
- Positive Stock Reaction: Following the earnings report, BDSX's stock surged 31.87% in pre-market trading to $7.21, reflecting investor optimism regarding the company's growth potential.
Biodesix Reports $88.5M Revenue for 2025, Up 24%
- Significant Revenue Growth: Biodesix anticipates total revenue of $88.5 million for 2025, representing a 24% increase, exceeding the upper limit of the company's revised guidance, indicating strong performance in the lung diagnostics sector.
- Lung Diagnostics Revenue Surge: The estimated lung diagnostics revenue for 2025 is $79.2 million, up 22% year-over-year, with Q4 revenue at $25.2 million, reflecting a 47% increase driven by higher test volumes and expanded reimbursement.
- Strong Cash Position: As of December 31, 2025, Biodesix reported cash and cash equivalents of $19.0 million, a 14% increase from Q3 2025, providing a solid financial foundation for future operations and investments.
- Positive Adjusted EBITDA Outlook: The company affirms expectations of positive Adjusted EBITDA for Q4 2025, indicating improving profitability supported by sustained revenue growth and operational leverage.
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
